The Potential Return on Public Investment in Detecting Adverse Drug Effects

Medical Care
Krista F HuybrechtsJerry Avorn

Abstract

Many countries lack fully functional pharmacovigilance programs, and public budgets allocated to pharmacovigilance in industrialized countries remain low due to resource constraints and competing priorities. Using 3 case examples, we sought to estimate the public health and economic benefits resulting from public investment in active pharmacovigilance programs to detect adverse drug effects. We assessed 3 examples in which early signals of safety hazards were not adequately recognized, resulting in continued exposure of a large number of patients to these drugs when safer and effective alternative treatments were available. The drug examples studied were rofecoxib, cerivastatin, and troglitazone. Using an individual patient simulation model and the health care system perspective, we estimated the potential costs that could have been averted by early systematic detection of safety hazards through the implementation of active surveillance programs. We found that earlier drug withdrawal made possible by active safety surveillance would most likely have resulted in savings in direct medical costs of $773-$884 million for rofecoxib, $3-$10 million for cerivastatin, and $38-$63 million for troglitazone in the United States through th...Continue Reading

References

Jan 16, 2003·The American Journal of Gastroenterology·David J GrahamDeborah Shatin
Mar 28, 2003·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Maryann Z SkrabalMichael S Monaghan
Apr 12, 2003·The American Journal of Medicine·David J GrahamParivash Nourjah
Jul 23, 2004·Pharmacoepidemiology and Drug Safety·Jennie T ChangLanh Green
Dec 2, 2004·JAMA : the Journal of the American Medical Association·David J GrahamRichard Platt
Dec 2, 2004·JAMA : the Journal of the American Medical Association·Bruce M PsatyNoel S Weiss
Dec 8, 2004·Lancet·Peter JüniMatthias Egger
Jan 26, 2005·Archives of Internal Medicine·Daniel H Solomon, Jerry Avorn
Feb 17, 2005·The New England Journal of Medicine·Robert S BresalierUNKNOWN Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators
Apr 26, 2007·Pharmacoepidemiology and Drug Safety·Li-Chia Chen, Darren M Ashcroft
Nov 30, 2007·The New England Journal of Medicine·Jerry Avorn
Jul 20, 2010·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Sten OlssonMary Couper
Dec 14, 2011·The New England Journal of Medicine·Jerry Avorn
Jul 20, 2012·The New England Journal of Medicine·Jerry Avorn
Aug 11, 2012·American Heart Journal·David MadiganJerry Avorn
May 3, 2014·Pharmacoepidemiology and Drug Safety·Joshua J GagneSebastian Schneeweiss
Jun 5, 2014·The New England Journal of Medicine·Bruce M Psaty, Alasdair M Breckenridge
May 6, 2016·Pharmacoepidemiology and Drug Safety·Katrina MottMarsha E Reichman
Jan 6, 2017·JAMA : the Journal of the American Medical Association·Aaron S Kesselheim, Jerry Avorn

❮ Previous
Next ❯

Citations

Apr 30, 2017·Medical Care·Elaine H Morrato

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.